We previously showed that KRAS drives the transcriptional upregulation of ACSL3 and ACSL4 in non-small cell lung cancer, and that this can be prevented by the inhibition of the mammalian target of rapamycin complex 1 (mTORC1) [20]. Here, ACSL3 is linked to non-small cell lung carcinoma.